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Abstract
Background: T-cell activation leads to signaling pathways that ultimately result in induction of
gene transcription from the interleukin-2 (IL-2) promoter. We hypothesized that the IL-2
promoter or its synthetic derivatives can lead to T-cell specific, activation-induced transgene
expression. Our objective was to develop a retroviral vector for stable and activation-induced
transgene expression in T-lymphocytes.
Results: First, we compared the transcriptional potency of the full-length IL-2 promoter with that
of a synthetic promoter composed of 3 repeats of the Nuclear Factor of Activated T-Cells (NFAT)
element following activation of transfected Jurkat T-cells expressing the large SV40 T antigen
(Jurkat TAg). Although the NFAT3 promoter resulted in a stronger induction of luciferase reporter
expression post stimulation, the basal levels of the IL-2 promoter-driven reporter expression were
much lower indicating that the IL-2 promoter can serve as a more stringent activation-dependent
promoter in T-cells. Based on this data, we generated a self-inactivating retroviral vector with the
full-length human IL-2 promoter, namely SINIL-2pr that incorporated the enhanced green
fluorescent protein (EGFP) fused to herpes simplex virus thymidine kinase as a reporter/suicide
"bifunctional" gene. Subsequently, Vesicular Stomatitis Virus-G Protein pseudotyped retroparticles
were generated for SINIL-2pr and used to transduce the Jurkat T-cell line and the ZAP-70-deficient
P116 cell line. Flow cytometry analysis showed that EGFP expression was markedly enhanced post
co-stimulation of the gene-modified cells with 1 µM ionomycin and 10 ng/ml phorbol 12-myristate
13-acetate (PMA). This activation-induced expression was abrogated when the cells were
pretreated with 300 nM cyclosporin A.
Conclusion:  These results demonstrate that the SINIL-2pr retrovector leads to activation-
inducible transgene expression in Jurkat T-cell lines. We propose that this design can be potentially
exploited in several cellular immunotherapy applications.
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Background
T-cells have several features that render them attractive tar-
get cells for cell and gene therapy applications. In addition
to their diverse and critical role in the immune system, T-
cells are readily available from human peripheral blood,
they can be easily isolated, activated, expanded to large
numbers in vitro, and reinfused with a potential to circu-
late for a long time in vivo. Indeed, T-cells have been suc-
cessfully utilized for adoptive immunotherapy of cancer,
viral infections, and autoimmune diseases.
Since adoptive transfer of allogeneic T-cells has been asso-
ciated with acute graft-versus-host disease (GVHD), a life-
threatening complication initiated by the donor alloreac-
tive T-cells against the normal host tissues, alternative
approaches have been attempted to reduce the risk of
GVHD while maintaining the beneficial aspects of this
treatment modality. One scenario was to use allogeneic T-
cells genetically-engineered to express the herpes simplex
virus thymidine kinase (HSVTK) suicide gene that would
lead to the depletion of the gene-modified T-cells follow-
ing treatment with the drug ganciclovir if GVHD arises [1].
This strategy gave promising results in a number of clini-
cal studies [2,3]. In a second approach, in vitro enriched
antigen-specific T-cells were used instead of total alloge-
neic T-cell populations to mount antiviral or antitumour
responses. Donor-derived cytomegalovirus (CMV)-spe-
cific cytotoxic T lymphocyte (CTL) clones were success-
fully used to treat patients suffering from CMV viral
infection following marrow transplants [4]. Similarly,
infusion of Epstein-Barr virus (EBV)-specific CTLs was
used to prevent and to treat EBV lymphoma in immuno-
compromised patients post BMT [5]. Interestingly, more
recent approaches in cancer immunotherapy investigated
the use of T-cells primed in vitro against minor histocom-
patibility antigens [6], or against tumor associated anti-
gens [7,8].
Moreover, autologous T-cells genetically engineered to
express antiviral transgenes have been used for the treat-
ment of HIV [9,10]. Similar studies investigated the use of
autologous T-cells engineered to express anti-inflamma-
tory cytokines for the treatment of autoimmune diseases
[11,12]. The success of these approaches is dependent on
the stable transfer of the therapeutic gene into all infused
T-cells and its subsequent expression upon T-cell activa-
tion. On the other hand, successful use of antigen-specific
T-cells is dependent upon their rapid in vitro selection and
enrichment. Therefore, stable and selective expression of a
gene marker in activated antigen-specific T-cells would
improve their therapeutic utility.
Integrating retroviral vectors have been successfully used
for stable expression of transgenes in T-cells [2,10,13].
Recently, the development of new retroviral pseudotypes
and improved transduction protocols have made it possi-
ble to gene modify T-cells with high efficiency [14]. Fur-
thermore, it was documented that the level of transgene
expression can vary with the activation status of T-cells
[15]. In fact, it has long been known that the enhancer
machinery within the retroviral long terminal repeat
(LTR) such as that of Moloney murine leukemia virus
(MoMLV) incorporates elements that confer transcrip-
tional preference to activated T-cells [16,17]. However,
LTR-driven transgene expression is neither exclusive to the
activated subset of gene-modified T-cells nor does it guar-
antee that all activated transduced T-cells express the
transgene if the vector integrates in a transcriptionaly
silent chromosomal background [18-20].
Activation of T-cells, physiologically by triggering of the T-
cell receptor (TCR) complex or pharmacologically by
using reagents such as ionomycin and PMA results in the
production of IL-2 which plays a key role in T-cell prolif-
eration and differentiation. Therefore, IL-2 gene transcrip-
tion by induction of the IL-2 promoter is specific to
activated T-cells [21]. Plasmid vectors in which reporter
gene expression is under the control of the full-length IL-
2 promoter or synthetic promoters composed of either
single or multiple binding motifs within the IL-2 pro-
moter have been used in many investigative studies of T-
cell activation [22-24]. In these studies, reporter gene
expression was induced following activation of the trans-
fected T-cell lines. Hence, we propose that incorporation
of the IL-2 promoter or its synthetic derivatives into a tran-
scriptionaly silent retroviral vector would lead to stable
and activation-induced transgene expression in T-cells.
Our objective is to develop a retroviral vector for stable
activation-induced transgene expression in T-lym-
phocytes.
In this study, we first compared the transcriptional
potency and stringency of the full-length IL-2 promoter
with that of a synthetic promoter composed of 3 NFAT
elements following stimulation of T-cells. Transient trans-
fections of Jurkat Tag cells with plasmids harboring either
one of the two promoters upstream of a luciferase reporter
showed that although the NFAT3 synthetic promoter
resulted in a stronger induction of reporter expression fol-
lowing T-cell activation, the IL-2 promoter had a more
stringent activation-dependent expression. Consequently,
we tested if a self-inactivating retroviral vector incorporat-
ing the full-length IL-2 promoter namely SINIL-2 pr
would serve as an integrated platform for stable and spe-
cific activation-induced transgene expression in T-cell
lines.Virology Journal 2006, 3:97 http://www.virologyj.com/content/3/1/97
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Results
Activation-induced luciferase reporter expression in Jurkat 
TAg cells
We compared the transcriptional capacity of the full-
length IL-2 promoter with that of a synthetic promoter
composed of 3 NFAT elements in transient transfection
assays using plasmids harboring either one of the two pro-
moters upstream of a luciferase reporter to determine
which would allow for more stringent T-cell activation-
dependent reporter expression. Jurkat T-cells expressing
the large T Ag were transfected with IL-2 promoter-luci-
ferase plasmid (Figure 1A) or NFAT3 promoter-luciferase
plasmid (Figure 1B). Co-stimulation of transfected cells
with 1 µM ionomycin and 10 ng/ml PMA for ~6 hr
resulted in 6.4 ± 0.4 – fold increase in IL-2 promoter-
driven luciferase reporter expression (P = 0.002) and 14.6
± 1.3 – fold increase in NFAT3 promoter-driven luciferase
expression (P = 0.008) which were both significant rela-
tive to transfected untreated cells or cells stimulated with
either drug alone (n = 3). Although T-cell activation
resulted in an average 2.3 ± 0.2 – fold stronger induction
capacity of luciferase reporter expression from the NFAT3
promoter compared to the IL-2 promoter (P < 0.001), the
basal transcriptional activity of the NFAT3 promoter in
the absence of T-cell activation was 4.6 ± 0.2 – fold higher
than that of the IL-2 promoter (P < 0.001). These results
indicated that the IL-2 promoter serves as more stringent
T-cell activation-dependent promoter than the synthetic
NFAT3 promoter.
Synthesis of the SINIL-2pr retrovector
To develop a retroviral vector for activation-induced sta-
ble transgene expression in T-cells, we generated a self-
inactivating retroviral vector (SIN) by creating extensive
deletions to the U3 region of the Moloney Murine Leuke-
mia Virus 3' long terminal repeat (3'LTR) in pGFP/TKfus
(Figure 2A). Retroviral promoter and enhancer machinery
were replaced by the full-length human IL-2 promoter as
described in the methods section. The resulting construct
SINIL-2pr incorporated the EGFP fused to HSVTK as a
reporter/suicide gene (Figure 2B). Subsequently, the
SINIL-2pr plasmid was stably transfected into the
293GPG packaging cell line to generate polyclonal as well
as single clone retroviral producer populations. Vesicular
Stomatitis Virus-G Protein (VSV-G) pseudotyped retropar-
ticles were produced and used to transduce the Jurkat T-
cell line and the ZAP-70-deficient Jurkat P116 T-cell line.
Since recombinant retroviral vectors can be be susceptible
to rearrangements prior to their final integration as a DNA
proviral genome, we characterized the integrated confor-
mation in transduced target cells by Southern Blot analy-
sis (Figure 2C). Genomic DNA was extracted from null &
from transduced Jurkat cells and P116 cells, digested with
KpnI and probed with [P32]-labeled DNA sequences com-
plementary to the GFP reporter cDNA. We detected DNA
bands consistent with the predicted sized fragment
expected from KpnI digest of integrated unrearranged pro-
viral DNA.
Cyclosporin-A-sensitive activation-induced EGFP 
expression in Jurkat cells transduced with SINIL-2pr 
retroparticles
In order to examine whether the SINIL-2pr configuration
leads to activation-induced expression in Jurkat T-cells, we
compared the level of EGFP reporter expression in Jurkat
T-cells transduced with SINIL-2pr retroparticles at a mul-
tiplicity of infection (MOI) of 5, (three consecutive trans-
duction rounds) following drug stimulation relative to
that of untreated cells (Figure 3). Mean EGFP expression
(MnX) was quantified at ~48 hr post -activation using
flow cytometry. Figure 3C shows the flow cytometry pro-
file of one representative experiment whereby a mixed
population of SINIL-2pr-transduced Jurkat T-cells had
detectable EGFP fluorescence (MnX = 3.22) relative to
control non gene-modified cells (MnX = 1.33, Figure 3A).
Since the SINIL-2pr design is expected to display a "self-
inactivation" phenotype with no expression driven from
the incorporated IL-2 promoter in the absence of any T-
cell activation, we speculated that this low level of EGFP
expression resulted from the basal level of activation in
Jurkat T-cells since these cells are dividing continuously in
culture. Co-stimulation of the mixed SINIL-2pr-trans-
duced population with 1 µM ionomycin and 10 ng/ml
PMA for ~6 hr resulted in enhanced EGFP reporter expres-
sion (MnX = 8.37, Figure 3D) as compared to stimulated
null cells (MnX = 1.62, Figure 3B). Results obtained from
three independent experiments (Figure 3E) showed an
average 2.0 ± 0.1 – fold increase (mean ± SEM) in relative
mean EGFP expression in SINIL-2pr – transduced Jurkat
cells following ionomycin and PMA treatment which was
significantly higher than that in untreated cells (P  =
0.011). This activation-induced expression was abrogated
when the cells were pretreated for 30 minutes with 300
nM CsA, a potent inhibitor of calcineurin and therefore of
the signal transduction cascade that leads to IL-2 pro-
moter transcriptional activation, indicating that the
enhanced expression of EGFP was under the regulatory
control of the IL-2 promoter.
Cyclosporin A-sensitive activation-induced EGFP 
expression in Jurkat P116 cells transduced with SINIL-2pr 
retroparticles
To determine if the low levels of EGFP reporter expression
obtained in Jurkat cells transduced with SINIL-2pr prior to
drug stimulation were indeed a consequence of basal state
of activation in this tumor T-cell line, we tested the SINIL-
2pr design in Jurkat P116 T-cells that are deficient in ZAP-
70, a kinase implicated in early steps in T-cell activation.
Though expandable in culture, Jurkat P116 cells exhibit a
longer doubling time compared to that of the parent cellVirology Journal 2006, 3:97 http://www.virologyj.com/content/3/1/97
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Activation-induced luciferase reporter expression in Jurkat TAg cells Figure 1
Activation-induced luciferase reporter expression in Jurkat TAg cells. A. Jurkat cells that express the large T Ag 
were transiently transfected by electroporation with an IL-2 promoter-luciferase construct. Co-stimulation of these T-cells 
with 1 µM ionomycin and 10 ng/ml PMA for ~6 hr resulted in 6.4 ± 0.4 – fold increase in IL-2 promoter-driven luciferase 
reporter expression relative to control non-stimulated cells (P = 0.002). B. Similar co-stimulation of Jurkat T Ag cells that were 
transfected with NFAT3 promoter-luciferase construct reulsted 14.6 ± 1.3 – fold increase in NFAT3 promoter-driven luci-
ferase expression relative to control (P = 0.008).Virology Journal 2006, 3:97 http://www.virologyj.com/content/3/1/97
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Design of the SINIL-2pr retrovector Figure 2
Design of the SINIL-2pr retrovector. A. pGFP/TKfus plasmid bears a full-length 3'LTR that incorporates all the promoter 
and enhancer machinery intrinsic to the wild-type MoMLV retrovirus. The CMV promoter element which substitutes the U3 
region in the 5' LTR drives the expression of the retroviral genome in transfected packaging cells for the production of replica-
tion-defective retrovirus. B. SINIL-2 pr retrovector is designed by creating an NheI-AscI deletion to the 3'LTR of pGFP/TKfus 
and by replacing the U3 with the full-length human IL-2 promoter which results in a self-inactivating retrovector whereby 
expression of the EGFP and HSVTK fusion protein is dependent on the IL-2 promoter in cells transduced with SINIL-2pr ret-
roparticles. C. Southern Blot analysis of the integrated proviral DNA in Jurkat and p116 cells transduced with SINIL-2pr retro-
vector at similar MOI. Genomic DNA was extracted from transduced and control null cells, digested with KpnI and probed 
with [P32]-labeled probe complementary to the GFP reporter cDNA. The detected DNA bands are consistent with the pre-
dicted sized fragment indicating no rearrangement in the integrated proviral DNA.Virology Journal 2006, 3:97 http://www.virologyj.com/content/3/1/97
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Activation-induced EGFP expression in Jurkat cells transduced with SINIL-2pr retroparticles Figure 3
Activation-induced EGFP expression in Jurkat cells transduced with SINIL-2pr retroparticles. A-D. Flow cytome-
try analysis of mean EGFP expression in Jurkat T-cells transduced with SINIL-2pr retroparticles relative to Jurkat null cells. 
Expression was measured at ~48 hr post-activation with 1 µM ionomycin and 10 ng/ml PMA relative to untreated cells. E. 
Cyclosporin A-sensitive induction of EGFP expression in Jurkat cells transduced with SINIL-2pr. Co-stimulation of the SINIL-
2pr-gene modified Jurkat T-cells with 1 µM ionomycin and 10 ng/ml PMA resulted in a 2.0 ± 0.1 – fold increase in relative mean 
EGFP expression measured at ~48 hrs (P = 0.011). This activation-induced EGFP expression was abrogated when the cells 
were pretreated for ~30 minutes with 300 nM CsA.Virology Journal 2006, 3:97 http://www.virologyj.com/content/3/1/97
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line reflecting a lower basal activation state (data not
shown). Figure 4 shows the flow cytometry profile of one
representative experiment whereby a mixed polyclonal
population of SINIL-2pr-transduced Jurkat P116 T-cells
showed level of EGFP fluorescence (MnX = 1.86, Figure
4C) that was similar to background fluorescence of con-
trol null cells (MnX = 1.12, Figure 4A). Co-stimulation of
the SINIL-2 pr-modified cells with 1 µM ionomycin and
10 ng/ml PMA for ~6 hr resulted in a marked increase in
EGFP reporter expression (MnX = 8.28, Figure 4D) as
compared to stimulated null cells (MnX = 1.16, Figure
4B). Moreover, following drug stimulation, there was a
clear-cut segregation between the EGFP-expressing popu-
lation and the EGFP-negative population. Results
obtained from three independent experiments (Figure 4E)
showed an average 3.4 ± 0.4 – fold increase in relative
mean EGFP expression in SINIL-2pr – transduced Jurkat
P116 cells following ionomycin and PMA treatment
which was significantly higher than that in untreated
transduced cells (P  = 0.029). This activation-induced
expression was inhibited when the Jurkat P116 cells were
pretreated for 30 minutes with 300 nM CsA.
Discussion
In this study, we first compared the transcriptional
potency of two T-cell activation-dependent promoters, the
IL-2 promoter and a synthetic promoter composed of 3
repeats of the NFAT element following pharmacological
stimulation of transiently transfected T-cells. Plasmid vec-
tors incorporating one of the two promoters were used to
transfer luciferase reporter expression into Jurkat T-cells
expressing the large T-antigen. Subsequent stimulation of
the cells with the drugs ionomycin (a calcium ionophore)
and PMA induces polyclonal T-cell activation by causing
direct and rapid increase in intracellular [Ca2+] [25].
Although the composite NFAT promoter resulted in
stronger induction of luciferase reporter expression fol-
lowing T-cell activation, the full-length IL-2 promoter had
much lower basal levels of luciferase reporter expression
in the absence of any stimulation (Figure 1). These results
indicate that unlike the synthetic NFAT promoter, the IL-
2 promoter in the plasmid background was strictly con-
troled as there was no considerable constitutive reporter
expression in un-stimulated cells. Furthermore, costimu-
lation with ionomycin and PMA resulted in a significant
increase in IL-2 promoter-driven luciferase expression
compared to unstimulated cells.
It was shown that reporter gene expression driven by the
full-length IL-2 promoter in transfected human peripheral
blood T lymphocytes and the Jurkat T- cell line paralleled
that of the endogenous IL-2 gene following T-cell activa-
tion [26]. Their results also indicated that the NFAT sites
were less implicated in transcriptional regulation in nor-
mal T cells than they were in the tumor T-cell line. A later
study showed that activation of NFAT element is insuffi-
cient for activation of the IL-2 promoter, and that the
NFAT and IL-2 promoters differ in their requirements for
co-stimulation [27]. Furthermore, Hooijberg E et al., used
a self-inactivating retroviral vector in which GFP reporter
expression was controlled by multiple (3 or 6) repeats of
NFAT elements followed by a minimal IL-2 promoter to
visualize and isolate antigen-stimulated Jurkat cells, pri-
mary T-cell blasts and antigen-specific T-cell clones [28].
Although the design resulted in activation-induced GFP
expression, the authors reported that a percentage of the
gene-modified T-cells expressed GFP constitutively inde-
pendently of activation. In addition, not all T-cells in an
antigen-specific clonal population had upregulated GFP
expression following activation. The sum of these studies
and our results suggest that the full-length IL-2 promoter
may serve as a more specific and stringent activation-
dependent promoter in T-cells.
Subsequently, we examined the potential of the full-
length IL-2 promoter within the context of a retroviral vec-
tor to drive stable and activation-induced reporter expres-
sion in transduced Jurkat T-cells. The cDNA for human IL-
2 promoter was incorporated into a self-inactivating retro-
viral vector replacing the enhancer and promoter machin-
ery in the 3'LTR of MoMLV. The resulting SINIL-2pr
construct incorporated EGFP fused to HSVTK as a
reporter/suicide gene (Figure 2). VSV-G pseudotyped ret-
roparticles were generated and were used to transduce the
Jurkat T-cell line. Flow cytometry analysis showed that
expression of the EGFP reporter was markedly enhanced
post co-stimulation of the gene-modified Jurkat T-cells
with ionomycin and PMA (Figure 3). Furthermore, activa-
tion-induced EGFP expression from the SINIL-2 design
was specific to induction of the IL-2 promoter as it was
sensitive to pre-treatment of the cells with cyclosporin A
(Figure 3E), an immunosuppressant drug that blocks IL-2
promoter transcriptional activation by interfering with the
enzymatic activity of the phosphatase calcineurin [29].
However, although there was no significant reporter
expression from the IL-2 promoter in the plasmid back-
bone, the SINIL-2 pr design did result in measurable EGFP
expression in unstimulated transduced Jurkat cells. We
speculated that this basal level of EGFP expression reflects
a basal status of activation in the Jurkat tumor T-cell line
since the cells are constantly dividing in culture that is not
the case for unactivated primary T-cells that are quiescent
in the absence of stimulation. To investigate this we trans-
duced the Jurkat P116 T-cells. Due to their defectiveness
in ZAP-70, a kinase involved in early steps of TCR signal-
ing, the cells divide at a much slower rate compared to the
parent cell line reflecting a lower basal status of activation.
However, since T-cell activation by co-stimulation with
ionomycin and PMA bypasses these early steps, JurkatVirology Journal 2006, 3:97 http://www.virologyj.com/content/3/1/97
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Activation-induced EGFP expression in Jurkat P116 cells transduced with SINIL-2pr retroparticles Figure 4
Activation-induced EGFP expression in Jurkat P116 cells transduced with SINIL-2pr retroparticles. A-D. Flow 
cytometry analysis of mean EGFP expression in Jurkat cells deficient for ZAP-70 (Jurkat P116) transduced with SINIL-2pr ret-
roparticles relative to null cells. Expression was measured at ~48 hr post-activation with 1 µM ionomycin and 10 ng/ml PMA 
relative to untreated counterparts. E. Cyclosporin A-sensitive induction of EGFP expression in Jurkat P116 cells transduced 
with SINIL-2pr. Co-stimulation of the SINIL-2pr- gene modified Jurkat P116 T-cells with 1 µM ionomycin and 10 ng/ml PMA 
resulted in a 3.4 ± 0.4 – fold increase in relative mean EGFP expression measured at ~48 hrs (P = 0.029). This activation-
induced EGFP expression was abrogated when the cells were pretreated for ~30 minutes with 300 nM CsA.Virology Journal 2006, 3:97 http://www.virologyj.com/content/3/1/97
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P116 cells can be activated with these drugs. Interestingly,
the Jurkat P116 cells transduced with SINIL-2 pr had
lower basal levels of EGFP expression compared to gene-
modified Jurkat cells (Figure 4). Furthermore, as specu-
lated, the mutant cells resulted in a stronger induction of
reporter expression following drug stimulation whereby
the segregation between the GFP +ve and the GFP -ve cells
was more evident.
Zhang P-X and Fuleihan RL used a recombinant adeno-
associated virus (AAV) vector incorporating the IL-2 pro-
moter to drive activation-dependent luciferase reporter
expression in the Jurkat T-cell line [30]. However, there
was low efficiency of gene transfer with very few clonal
AAV integration events. Despite in vitro selection in G418,
some of the transferred material was lost or silenced over
time. Furthermore, to induce luciferase reporter expres-
sion following T-cell activation, the cells had to be sub-
jected to additional stimulation such as heat shock and
irradiation due to the nature of the vector used. Hence,
taking all this into consideration, the AAV system would
be greatly limited if applied to primary T-cells.
Since cytotoxic CD8+ T-cells do not significantly induce
IL-2 promoter as compared to CD4+ T-cells, we propose
that the SINIL-2pr system would be especially useful in
applications such as negative selection of alloreactive
CD4+ T-cells when the disparity between donor and recip-
ient is at the MHC Class II locus and for preferential
enrichment of antigen-specific CD4+ T-cells which have
been shown to confer an advantage in several immuno-
therapy applications. In one study, unselected donor T-
lymphocytes with a predominance of CD4+ population
resulted in a stronger expansion of virus-specific T-cells
[31]. Similarly, another study showed that there was a
strikingly higher proportion of CD4+ EBV-specific T-cells
transduced after early sensitization with EBV-presenting
B-cells [19]. In adoptive immunotherapy of cancer, CD4+
T-cells were also shown to play an essential role by provid-
ing early stimuli for proliferation of tumor-reactive T-cells
[32]. In addition, co-expression of the EGFP reporter and
the HSVTK suicide gene as a fusion protein in the SINIL-
2pr design allows not only for selection of the engineered
T-cells but also conditional destruction following GCV
treatment. The utility of the EGFP-HSVTK fusion as a
"bifunctional" reporter/suicide transgene and its potential
use in primary human T-cells was already demonstrated
in previously published work by our group [33].
Conclusion
We conclude that the SINIL-2 pr design can serve as plat-
form for stable, specific, and activation-induced expres-
sion in T-cell lines. Further experiments need to be done
to investigate the function of this system in primary T-cells
and to exploit its use in several T-cell immunotherapy
applications such as negative selection of alloreactive T-
cells and their elimination from the donor T-cell popula-
tion prior to infusion or for ex vivo sorting of antigen-spe-
cific T-cells and their subsequent in vivo tracking.
Methods
Cell lines and plasmids
The IL-2 promoter-luciferase plasmid (IL-2Luc) and the
NFAT3 promoter-luciferase plasmid (NFATLuc) were pre-
viously described [34]. The Jurkat human acute lymphob-
lastic leukemia T-cell line was obtained from the
American Type Culture Collection (ATCC, Rockville,
MD). Jurkat cells expressing the SV40 large T antigen (Jur-
kat TAg) were previously described [34]. ZAP-70-deficient
Jurkat P116 cells were generously provided by Dr. R. T.
Abraham (Department of Immunology, Mayo Clinic,
Minnesota). All T-cell lines were maintained in RPMI
media (Gibco-BRL, Gaithesburg, MD) supplemented with
10% heat-inactivated FBS (Gibco-BRL) and 1% penicillin-
streptomycin. pJ6Ω Bleo plasmid and 293GPG retroviral
packaging cell line were generous gifts from Dr. Richard.
C. Mulligan (Children's Hospital, Boston, MA). 293GPG
cells were maintained in media composed of DMEM
(Gibco-BRL), 10% heat-inactivated FBS supplemented
with 0.3 mg/ml G418 (Mediatech, Herndon, VA), 2 µg/ml
puromycin (Sigma, Oakville, ONT), and 1 µg/ml tetracy-
cline (Fisher Scientific, Nepean, ONT).
Transfection of Jurkat TAg cells and drug stimulation
20 × 106 Jurkat T-cells expressing the large T antigen were
co-transfected with a total of ~10 µg DNA of either the IL-
2 promoter-luciferase or the NFAT3 promoter-luciferase
plasmid and PEF-GFP (empty vector) at a ratio of 10:1. A
control sample was transfected with ~10 µg PEF-GFP DNA
only to normalize for the efficiency of transfection. Tran-
sient transfections were performed using standard electro-
poration at 960 µF and 240 V (Bio-Rad, Hercules, CA).
The samples were then cultured in 75-cm2 tissue culture
flasks in complete RPMI media at 37°C and 5%CO2 for
two days. Afterwards, samples were analyzed by flow
cytometry (FACStar sorter, Becton Dickinson, Mountain
View, CA) to determine transfection efficiency based on
EGFP fluorescence. Each sample was then divided into 4
subsets that were either stimulated with 1 µM ionomycin
(Sigma, St. Louis, MO) or/and 10 ng/ml PMA (Sigma) or
left untreated for ~6 hr.
Luciferase assays
Transfected Jurkat TAg cells were harvested ~6 hr post
stimulation and washed twice with phosphate-buffered
saline (PBS). Afterwards, cells in each sample were lysed
using 250 µl lysis buffer (Luciferase Reporter Gene Assay,
Boehringer Mannheim). Then, a 20 µl aliquot of each
lysate supernatant was mixed with 50 µl luciferase reagent
buffer containing the luciferin substrate (LuciferaseVirology Journal 2006, 3:97 http://www.virologyj.com/content/3/1/97
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Reporter Gene Assay, Boehringer Mannheim). Within 30
sec of starting the reaction per sample, luciferase activity
was measured as light units based on light emission at 562
nm using the Lumat LB-9507 luminometer (Perkin Elmer
Instruments, Rodgau-Juegesheim, Germany) according to
manufacturer's specifications. All measurements were
done in triplicates.
SINIL-2pr retrovector design and synthesis
We used a derivative of pGFP/TKfus [33] to generate the
SINIL-2pr design. pGFP/TKfus contains the cDNA for the
enhanced green fluorescent protein (EGFP) reporter and
the herpes simplex virus thymidine kinase (HSVTK) sui-
cide gene as a fusion and incorporates the CMV promoter
in the 5'LTR which drives expression in transfected viral
packaging cells. We derived a self-inactivating (SIN) vec-
tor from this plasmid by creating a 341-bp NheI-AscI/Kle-
now deletion in the 3'LTR to remove all the retroviral
promoter and enhancer machinery. An insert encoding
for the human IL-2 promoter (-372 to +48) was generated
by PCR (PTC-100™ Programmable Thermal Controller,
MJ Research Inc.) using CTA GCT AGC (introducing NheI
site) GAA AGG AGG AAA AAC TGT TTC AT sense primer
and C GAG CTC (introducing Ecl136II site) TAG GGA AC
T CTT GAA CAA GAG antisense primer (Sheldon Biotech-
nology Centre, McGill University, Montreal). The ampli-
fied insert was then digested with the corresponding
enzymes, purified, and ligated into the SIN-derivative in
order to generate the SINIL-2pr plasmid (Figure 2). Nucle-
otide sequences of the mutated 3'LTR and the inserted IL-
2 promoter were confirmed by DNA sequencing (GenA-
lyTic Inc., University of Guelph, Ontario).
Generation of the SINIL-2pr retroviral producers and 
production of VSV-G pseudotyped retroviral particles
The SINIL-2pr retroviral producers were generated by sta-
ble transfection of the 293GPG packaging cell line as pre-
viously described [35]. In brief, stable producer cells were
generated by co-transfection of 5 µg FspI-linearized SINIL-
2pr retrovector and pJ6Ω Bleo plasmid at a 10:1 ratio.
Transfected packaging cells were subsequently selected in
293GPG media supplemented with 100 µg/ml Zeocin
(Invitrogen, San Diego, CA) for 3–4 weeks. Resulting sta-
ble polyclonal as well as isolated single clone producer
populations were utilized to generate VSV-G pseudotyped
retroviral particles. All viral supernatants were filtered
through 0.45-µm pore size syringe-mounted filters (Gel-
man Sciences, Ann Arbor, MI) and stored at -20°C. Subse-
quent 100 × concentration of the retroviral preparations
was performed using ultracentrifugation according to a
previously described procedure [35] after which samples
were stored at -80°C.
SINIL-2pr viral titer determination and RCR assay
Jurkat T-cells were suspension-cultured in 12-well plates
at ~2 × 105 cells per well per 1 ml of the concentrated ret-
roviral sample serially diluted in complete RPMI media
supplemented with 6 µg/ml Polybrene (Sigma). Cells
transduced with the various viral dilutions were then
incubated overnight at 37°C and 5 % CO2. Afterwards,
the samples were spun at 1000 g for 5 min to pellet the
cells and the virus-containing supernatent was discarded.
The cells for each sample were re-suspended in 2 ml fresh
complete RPMI media and expanded in culture. FACS
analysis was performed on these samples on 5th day post
transduction to ascertain retrovector expression and gene
transfer efficiency as measured by EGFP fluorescence.
Based on the number of target cells per well per dilution
sample at the time of viral addition and assuming that
each cell takes 1 retroparticle when the gene transfer is not
saturated (less than 40%), the viral titer was estimated as
~1 × 107 infectious particles per ml. Viral preparations
were devoid of replication competent retrovirus (RCR) as
determined by standard EGFP marker rescue assay per-
formed on null untransduced Jurkat cells exposed to con-
ditioned supernatant collected from transduced Jurkat
cells.
Transduction of Jurkat and P116 T-cell lines, Southern 
Blot, and drug stimulation
Each of Jurkat and P116 T-cell lines was suspension-cul-
tured at ~2 × 105 cells per well per 1 ml of complete RPMI
media. The cells were transduced with SINIL-2pr concen-
trated retrovirus at an MOI of 5 in whole media supple-
mented with 6 µg/ml Polybrene. This procedure was
repeated daily for ~6 hr exposure for three consecutive
days after which stably transduced cells were expanded.
No clonal selection was performed, and mixed popula-
tions of transduced cells were used for all subsequent
experiments. Southern blot analysis was performed on 15
µg of overnight KpnI digested genomic DNA extracted
from stably transduced cells as well as untransduced con-
trol cells. Blots were hybridized with P32 labeled cDNA
probes, washed and exposed on photographic film. T-cell
stimulation was done using 1 µM ionomycin and/or 10
ng/ml PMA in whole media for ~6 hr and in some exper-
iments following 30 min exposure to 300 nM cyclosporin
A (CsA) (Novartis Pharma Canada Inc.). FACS analysis
was performed to ascertain retrovector expression as
measured by mean EGFP fluorescence of positively gated
cells.
Statistics
Student T test was applied using Microsoft Excel software.
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